Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease

Experimental Neurology

Volumn 159, Issue 2, 1999, Pages 362-376

  Singhrao, S K ^a   Neal, J W ^a   Morgan, B P ^a   Gasque, P ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C9; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN; MYELIN;

ADULT; AGED; ARTICLE; ASTROCYTOSIS; CAPSULA INTERNA; CAUDATE NUCLEUS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORPUS STRIATUM; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; MICROGLIA; NERVE CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0032873347     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7170     Document Type: Article

References (54)

1. Allsop D., Landon M., Kidd M., Lowe J. S., Reynolds G. P., Gardner A. Monoclonal antibodies raised against a subsequence of cerebrovascular amyloid in Alzheimer's disease. Neurosci. Lett. 68:1986;252-256.
2. Andrew S. E., Goldberg Y. P., Kremer B., Telenius H., Theilmann J., Adam S., Starr E., Squitieri F., Lin B., Kalchman M. A., Graham R. K., Hayden M. R. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nature Genet. 4:1993;398-403.
3. Asghar S. S. Pharmacological manipulation of the complement system. Pharmacol. Rev. 36:1984;223-244.
4. Barnum S. R. Complement biosynthesis in the central nervous system. Crit. Rev. Oral. Biol. Med. 6:1995;132-139.
5. Bradt B. M., Kilb W. P., Cooper N. R. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J. Exp. Med. 188:1998;431-438.
6. Breitner J. C. S. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu. Rev. Med. 47:1996;401-411.
7. Browne S. E., Ferrante R. J., Beal M. F. Oxidative stress in Huntington's disease. Brain Pathol. 9:1999;147-163.
8. Cross R. B. Demonstration of neurofibrillary tangles in paraffin sections. A quick and simple method using Palmgrens method. Med. Lab. Sci. 39:1982;67-69.
9. Davies S. W., Turmaine M., Cozens B. A., DiFiglia M., Sharp A. H., Ross C. A., Scherzinger E., Wanker E. E., Mangiarini L., Bates G. P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:1997;537-548.
10. DeBruijn M. H. L., Fey G. H. Human complement component C3: cDNA coding sequence and derived primary structure. Proc. Natl. Acad. Sci. USA. 82:1985;708-712.
11. DiFiglia M., Sapp E., Chase K., Schwarz C., Meloni A., Young C., Martin E., Vonsattel J-P., Carraway R., Boyce F. M., Aronin N. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. 14:1995;1075-1081.
12. Discipio R. G., Gehring M. R., Podack E. R., Kan C. C., Hugli T. E., Fey G. H. Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9. Proc. Natl. Acad. Sci. USA. 81:1984;7298-7302.
13. Eikelenboom P., Hack C. E., Rozemuller J. M., Stam F. C. Complement activation in amyloid plaques in Alzheimer's dementia. Virch. Arch. B Cell Pathol. 56:1989;259-262.
14. Ferrante R. J., Kowall N., Beal M. F., Richardson E. P. Jr, Bird E., Martin J. B. Selective sparing of a class of striatal neurons in Huntingtons disease. Science. 230:1985;561-563.
15. Gasque P., Singhrao S. K., Neal J. W., Gotze O., Morgan B. P. Expression of the receptor for complement C5a (CD88) is upregulated on reactive astrocytes, microglia and endothelial cells in inflammed human central nervous system. Am. J. Pathol. 150:1997;31-41.
16. Gasque P., Singhrao S. K., Neal J. W., Morgan B. P. C3aR is a marker of inflammation and gliosis in human neurodegenerative disorders. Mol. Immunol. 35:1998;380.
17. Gasque P., Singhrao S. K., Neal J. W., Wang P., Sayah S., Fontaine M., Morgan B. P. The receptor for complement anaphylatoxin C3a is expressed by Myeloid cells and nonmyeloid cells in inflamed human central nervous system: Analysis in multiple sclerosis and bacterial meningitis. J. Immunol. 160:1998;3543-3547.
18. Gasque P., Chan P., Fontaine M., Ischenko A., Lamacz M., Gotze O., Morgan B. P. Identification and characterisation of the complement C5a anaphylatoxin receptor on human astrocytes. J. Immunol. 155:1995;4882-4888.
19. Gasque P., Jones J., Singhrao S. K., Morgan B. P. Identification of an astrocyte cell population from human brain that expresses perforin, a cytotoxic protein implicated in immune defense. J. Exp. Med. 187:1998;451-460.
20. Graeber M. B., Bise K., Mehraein P. CR3/43, a marker for activated human microglia: application to diagnostic neuropathology. Neuropathol. Appl. Neurobiol. 20:1994;406-408.
21. Graveland G. A., Williams R., DiFiglia M. Evidence for degenerative changes in neostriatal spiny neurons in Huntington's disease. Science. 227:1985;770-773.
22. Haque N. S. K., Borghesani P., Isacson O. Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder. Molec. Med. Today. 4:1997;175-183.
23. Huntington G. On Chorea. Med. Surg. Rep. 26:1872;320-321.
24. Cell. 72:1993;971-983.
25. King G., Payne S., Walker F., Murray G. I. A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. J. Pathol. 183:1997;237-241.
26. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S. W., Bates G. P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
27. Matthews R. T., Yang L., Browne S., Baik M., Beal M. F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA. 95:1998;8892-8897.
28. McGeer P. L., McGeer E. G. The inflammatory response system of the brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21:1995;195-218.
29. Morgan, B. P.1993. Complement in Health and Disease (2nd Edn). Edited by K. Whaley, M. Loos, and J. M. Weiler. Kluwer, pp 353-375.
30. Morgan B. P., Gasque P. Expression of complement in the brain: Role in health and disease. Immunol. Today. 17:1996;461-466.
31. Muhleisen H., Gehrmann J., Meyermann R. Reactive microglia in Creutzfeldt-Jakob disease. Neuropathol. Appl. Neurobiol. 21:1995;505-517.
32. Obanion M. K., Finch C. E. Inflammatory mechanisms and anti-inflammatory therapy in Alzheimer's disease. Neurobiol. Aging. 17:1996;669-673.
33. Pasinetti G. M. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: The role of the Complement system. Neurobiol. Aging. 17:1996;707-716.
34. Portera-Cailliau C., Hedreen J. C., Price D. L., Koliatsos V. E. Evidence for apoptotic cell death in Huntington's disease and excitotoxic animal models. J. Neurosci. 15:1995;3775-3787.
35. Quarrell, O, and, P. S. Harper, 1991, The clinical neurology of Huntingtons disease. In, Huntingtons Disease: major problems in neurology 22 chapter 2, pages, 37, - 81, ed, P. S. Harper, WB Saunders Company.
36. Rogers J., Cooper N. R., Webster S., Schulz J., McGeer P. L., Styren S. D., Civin W. H., Brachova L., Bradt P., Ward P., Leiberburg I. Complement activation by b-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 89:1992;10016-10020.
37. Sharp A. H., Loev S., Schilling G., Li S. H., Li X. J., Bao J., Wagster M. V., Kotzuk J. A., Steiner J. P., Lo A. Widespread Expression of Huntingtons Disease gene (IT15) Protein Poduct. Neuron. 14:1995;1065-1074.
38. Sim, R. B.1998. The complement system. In Topley and Wilsons Microbiology and Microbial Infections. 9th Edition, vol 3. eds. L. Collier, A. Balowest Sussmann. Complement, chapter 4, pages 37-45. Arnold Publishers, London.
39. Singhrao S. K., Neal J. W., Gasque P., Morgan B. P., Newman G. R. Complement in the aetiology of Picks disease. J. Neuropath. Exp. Neurol. 55:1996;578-593.
40. Singhrao S. K., Thomas P., Wood J. D., MacMillan J. C., Neal J. W., Harper P. S., Jones A. L. Huntingtin protein colocalises with lesions of neurodegenerative diseases: an investigation in Huntington's, Alzheimer's and Pick's disease. Exp. Neurol. 150:1998;213-222.
41. Snell R. G., MacMillian J. C., Cheadle J. P., Fenton I., Lazarou L. P., Davis P., MacDonald M. E., Gusella J. F., Harper P. S., Shaw D. J. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntingtons disease. Nature Genet. 4:1993;393-397.
42. Strong T. V., Tangle D. A., Valdes J. M., Elmer L. W., Boehm K., Swaroop M., Kaatz K. W., Collins F. S., Albin R. A. Widespread expression of the human and rat Huntingtons disease gene in brain and non-neural tissues. Nature Genet. 5:1993;259-265.
43. Svensson M., Liu L., Mattsson P., Morgan B. P., Aldskogius H. Evidence for activation of the terminal pathway of complement and upregulation of sulfated glycoprotein (SGP-2) in the hypoglossal nucleus following peripheral nerve injury. Mol. Chem. Neuropathol. 24:1995;53-68.
44. Svensson M., Aldskogius H. The effect of axon injury on microtubule-associated protein MAP2 mRNA in the hypoglossal nucleus of the adult rat. Brain Res. 581:1992;319-322.
45. Trottier Y., Lutz Y., Stevanin G., Imbert G., Devys D., Cancel G., Sandou F., Weber C., David G., Tora L., Agid Y., Brice A., Mandel J-L. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature. 378:1995;403-406.
46. Veerhuis R., Janssen I., Hack C. E., Eikelenboom P. Early complement components in Alzheimer's disease brains. Acta Neuropathol. 91:1996;53-60.
47. Velazquez P., Cribbs D. H., Poulos T. L., Tenner A. J. Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis. Nature Med. 3:1997;77-79.
48. Vonsattel J-P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D., Richardson E. P. Jr. Neuropathologic characterization of Huntingtons disease. J. Neuropath. Exp. Neurol. 44:1985;559-577.
49. Vonsattel J. P. G., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57:1998;369-384.
50. Walker D. G., Kim S. U., McGeer P. L. Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. J. Neurosci. Res. 40:1995;478-493.
51. Watson M. D., Roher A. E., Kim K. S., Spiegel K., Emmerlimg M. R. Complement interactions with amyloid-β1-42: a nidus for inflammation in AD brains. Int. J. Exp. Clin. Invest. 4:1997;147-156.
52. Webster S., Lue L-F., Brachova L., Tenner A. J., McGeer P. L., Terai K., Walker D. G., Bradt B., Cooper N. R., Rogers J. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging. 18:1997;415-421.
53. Wellington C., Brinkman J. R., Kusky O., Hayden M. R. Towards understanding the molecular pathology of Huntingtons disease. Brain Pathol. 7:1997;979-1002.
54. Yasuhara O., Yoshinari A., McGeer E., McGeer P. L. Expression of the complement membrane attack complex and its inhibitors in Pick disease brain. Brain Res. 652:1994;346-349.